Predicting human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomics

• US 10,473,641 B2
• Filed: 04/21/2014
• Issued: 11/12/2019
• Est. Priority Date: 03/22/2010
• Status: Active Grant

• Current Assignee: Stemina Biomarker Discovery Incorporated
• Original Assignee: Stemina Biomarker Discovery Incorporated
• Inventors: West, Paul R., Weir-Hauptman, April M., Smith, Alan M., Donley, Elizabeth L. R., Cezar, Gabriela G.
• Primary Examiner(s): Ton, Thaian N
• Application Number:
  US14/257,299
• Publication Number:
  US 20140273069A1
• Time in Patent Office: 2,031 Days
• CPC Class Codes: G01N 33/5014 for testing toxicity
• CPC Class Codes: G01N 33/5073 Stem cells
• CPC Class Codes: G01N 33/6848 Methods of protein analysis involving mass spectrometry

Abstract

The invention provides biomarker profiles of metabolites and methods for screening chemical compounds including pharmaceutical agents, lead and candidate drug compounds and other chemicals using human stem-like cells (hSLCs) or lineage-specific cells produced therefrom. The inventive methods are useful for testing toxicity, particularly developmental toxicity and detecting teratogenic effects of such chemical compounds. Specifically, a more predictive developmental toxicity model, based on an in vitro method that utilizes both hSLCs and metabolomics to discover biomarkers of developmental toxicity is disclosed.

Claims

1. A method of predicting human developmental toxicity of a test compound, the method comprising the steps of:

(a) culturing human stem-cell like cells (hSLCs);

(i) in the presence of a first known developmental toxicant; and

(ii) in the absence of the first known developmental toxicant;

(b) detecting a plurality of metabolites having a molecular weight of less than about 3000 Daltons associated with hSLCs exposed to the first known developmental toxicant in comparison with hSLCs not exposed to the first known developmental toxicant in order to identify a difference in metabolic response of hSLCs exposed to the first known developmental toxicant in comparison with hSLCs not exposed to the first known developmental toxicant;

wherein the plurality of metabolites is detected by mass spectrometry;

(c) generating a set of mass features associated with exposure of hSLCs to the first developmental toxicant by analyzing the difference in metabolic response;

(d) repeating steps a)-c) multiple times, each time with a different known developmental toxicant;

(e) grouping mass features generated from each exposure to a developmental toxicant to obtain a reference profile of mass features correlating with developmental toxicity;

(f) culturing hSLCs;

(i) in the presence of a test compound; and

(ii) in the absence of the test compound;

(g) detecting a plurality of metabolites having a molecular weight of less than about 3000 Daltons associated with hSLCs exposed to the test compound in comparison with hSLCs not exposed to the test compound in order to identify a difference in metabolic response of hSLCs exposed to the test compound in comparison with hSLCs not exposed to the test compound;

wherein the plurality of metabolites is detected by mass spectrometry; and

(h) generating a set of mass features associated with exposure of hSLCs to the test compound by analyzing the difference in metabolic response;

(i) comparing the set of mass features associated with exposure of hSLCs to the test compound of step (h) to the reference profile of mass features correlating with developmental toxicity of step (e) to predict the human developmental toxicity of the test compound.

2. The method of claim 1, wherein the hSLCs cultured in the absence of a known developmental toxicant are further cultured during step a) and/or step (f) in the presence of a known non-developmental toxicant.

3. The method according to claim 1, wherein the hSLCs comprise human embryonic stem cells (hESCs), human induced pluripotent (iPS) cells, or human embryoid bodies.

4. The method according to claim 1, wherein the reference profile comprises a biomarker profile characteristic of hSLC response to a developmental toxicant.

5. The method according to claim 1, wherein the mass spectrometry is liquid chromatography/electrospray ionization mass spectrometry.

6. The method according to claim 1, wherein the reference profile of mass features correlating with developmental toxicity comprises five or more of the small molecules listed in Table 8.

7. The method according to claim 1, wherein the reference profile of mass features correlating with developmental toxicity comprises ten or more of the small molecules listed in Table 8.

8. The method according to claim 1, wherein the reference profile of mass features correlating with developmental toxicity comprises one or more of the small molecules listed in Table 10.

9. The method according to claim 1, wherein the reference profile of mass features correlating with developmental toxicity comprises the fifteen small molecules listed in Table 10.

10. The method according to claim 1, wherein mass spectrometry comprises gas phase ion spectrophotometer and/or laser-desorption/ionization mass spectrometry.

11. The method according to claim 1, wherein mass spectrometry comprises matrix assisted laser desorption/ionization (MALDI) mass spectrometry and/or surface-enhanced laser desorption/ionization (SELDI).

12. The method according to claim 1, wherein mass spectrometry comprises MALDI/TOF (time-of-flight), SELDI/TOF, liquid chromatography-mass spectrometry (LC-MS), gas chromatography-mass spectrometry (GC-MS), high performance liquid chromatography-mass spectrometry (HPLC-MS), capillary electrophoresis-mass spectrometry, nuclear magnetic resonance spectrometry, tandem mass spectrometry, secondary ion mass spectrometry (SIMS), and/or ion mobility spectrometry.

13. The method according to claim 1, wherein culturing the hSLCs in the presence of a known developmental toxicant of step (a) comprises culturing hSLCs at a dose of the known developmental toxicant selected from:

a dose corresponding to the EC50 or IC50 concentration of the known developmental toxicant;

a dose below the EC50 or IC50 concentration of the known developmental toxicant;

or

a dose of the known developmental toxicant equivalent to the circulating concentration in maternal serum.

14. The method according to claim 1, wherein culturing the hSLCs in the presence of test compound comprises culturing hSLCs at a dose of the test compound selected from:

a dose representing the EC50 or IC50 concentration of the test compound;

a dose below the EC50 or IC50 concentration of the test compound;

or

a dose of the test compound equivalent to the circulating concentration in maternal serum.

15. The method according to claim 1, wherein the known developmental toxicant is selected from diphenylhydantoin, methotrexate, 5-fluorouracil, accutane, amiodarone, busulfan, carbamazepine, cyclophosphamide, cytosine arabinoside, hydroxyurea, retinoic acid, rifampicin, thalidomide, and/or valproic acid.

16. The method according to claim 1, wherein step (a) is repeated for each of the known developmental toxicants 5-fluorouracil, busulfan, cytosine arabinoside, hydroxyurea, retinoic acid, thalidomide, and valproic acid.

17. The method according to claim 16, wherein the reference profile of mass features correlating with developmental toxicity comprises the 142 mass features shown in Table 4.

18. The method according to claim 16, wherein step (a) is further repeated for each of the known developmental toxicants diphenylhydantoin, methotrexate, accutane, amiodarone, carbamazepine, cyclophosphamide, and rifampicin.

19. The method according to claim 2, wherein step (a) is repeated for each of the known developmental toxicants and known non-developmental toxicants shown in Table 11.

20. The method according to claim 19, wherein the reference profile of mass features correlating with developmental toxicity comprises the 15 mass features shown in Table 10.

21. A method of producing a reference profile of mass features correlating with developmental toxicity, the method comprising the steps of:

(a) culturing human stem-cell like cells (hSLCs);

(i) in the presence of a first known developmental toxicant; and

(ii) in the absence of the first known developmental toxicant;

(b) detecting a plurality of metabolites having a molecular weight of less than about 3000 Daltons associated with hSLCs exposed to the first known developmental toxicant in comparison with hSLCs not exposed to the first known developmental toxicant in order to identify a difference in metabolic response of hSLCs exposed to the first known developmental toxicant in comparison with hSLCs not exposed to the first known developmental toxicant;

wherein the plurality of metabolites is detected by mass spectrometry;

(c) generating a set of mass features associated with exposure of hSLCs to the first developmental toxicant by analyzing the difference in metabolic response;

(d) repeating steps a)-c) multiple times, each time with a different known developmental toxicant;

(e) grouping mass features generated from each exposure to a developmental toxicant to obtain a reference profile of mass features correlating with developmental toxicity.

22. The method of claim 21, wherein the hSLCs cultured in the absence of a known developmental toxicant are further cultured during step a) in the presence of a known non-developmental toxicant.